MetadataShow full item record
According to IARC figures ‘rare and less common’ cancers comprise more than a third of all cancer diagnoses as a group. However, advances in molecular biology have resulted in novel ways to classify cancers based upon genetic alterations and not just anatomical location, and this revised classification is at the heart of any move toward more personalized healthcare. It is now increasingly accepted that cancer should be thought of as many hundreds of more rare subtypes, each of which will have specific therapeutic options. We have selected colorectal carcinoma to illustrate the concept that each cancer is ‘rare’, and demonstrate why this is important for delivering on the concept of Predictive, Preventive and Personalized Medicine (PPPM) for cancer in terms of prediction of who will get the disease, how it will behave and how to prevent it.
Showing items related by title, author, creator and subject.
Pericytes promote malignant ovarian cancer progression in mice and predict poor prognosis in serous ovarian cancer patientsSinha, D.; Chong, L.; George, J.; Schlüter, H.; Mönchgesang, S.; Mills, S.; Li, J.; Parish, C.; Bowtell, D.; Kaur, Pritinder (2016)Purpose: The aim of this study was to investigate the role of pericytes in regulating malignant ovarian cancer progression. Experimental Design: The pericyte mRNA signature was used to interrogate ovarian cancer patient ...
Casari, I.; Falasca, Marco (2015)Pancreatic cancer is without any doubt the malignancy with the poorest prognosis and the lowest survival rate. This highly aggressive disease is rarely diagnosed at an early stage and difficult to treat due to its resistance ...
Ferro, R.; Falasca, Marco (2014)Pancreatic cancer is a highly aggressive tumour that is very resistant to treatments and it is rarely diagnosed early because of absence of specific symptoms. Therefore, the prognosis for this disease is very poor and it ...